St. Renatus Secures Additional $5 Million Funding from Blue Ocean

Start Discussion
Capital commitment to be used to help transition St. Renatus from a research company that developed the first Nasal Mist Technology for Dental Anesthesia toward a commercialization company
Posted: March 19, 2014
FORT COLLINS, Colo. – March 18, 2014 – St. Renatus, LLC announced today that additional funding
has been committed by Blue Ocean STR, LLC to assist St. Renatus with completing the New Drug
Application (NDA) submission to the U.S. Food and Drug Administration (FDA). The $5 million
investment will also support St. Renatus’ transition to a commercialization company to market a new
nasal mist anesthetic technology that it has been developing and testing for dental anesthesia for the
past four years.

St. Renatus has completed all planned Phase 3 pivotal clinical trials for this investigative drug. It is
preparing its data analysis for submission in 2014 to the FDA for use on adult and pediatric dental
patients without the use of a needle injection.

“Blue Ocean was an early investor in St. Renatus, and we continue to be excited about the company’s
prospects,” said Curt Richardson, co-founder and co-owner of Blue Ocean Holdings in Fort Collins,
Colo. “We recognized the blockbuster potential of the St. Renatus investigative drug, which fits our
investment strategy of supporting companies that can change lives and transform their industries.”
Blue Ocean Holdings, LLC is a diversified investment management company with two primary portfolios
focused on innovative business ventures and commercial real estate.

Blue Ocean Holdings’ affiliated companies benefit from Richardson’s proven model of successfully
building companies. Along with investing, the company takes an active role in mentoring companies –
Kurt Hoeven, the CEO of Blue Ocean Holdings, has joined the board of St. Renatus. His expertise in
the management of numerous fast-growth companies in a variety of industries is an asset to St.
Renatus.

“Blue Ocean’s commitment to St. Renatus is an asset to a fast growing company looking at national
distribution. We want to ramp up production and distribution quickly -- if our drug application is
approved by the FDA. Often there is lag time in the expenses incurred during the ramp up versus sales
revenue, therefore we are actively seeking additional private investors like Blue Ocean and new
investors to support us financially during this exciting period,” said Steve Merrick, Chief Executive
Officer for St. Renatus, LLC.
Views: 37
Start Discussion
Dentaltown Magazine
May 2026
Dentaltown Magazine May 2026 Read Current Issue Read Archived Issues
Sponsors
Townie Perks
Townie® Poll
What’s actually driving most of your new patient flow right now?
  
Site Menu
Message Boards Magazine Continuing Education Podcasts Pods & Blogs Classifieds Dental News Events Townie® Poll Ebooks Townie Choice Awards
Company Info
Contact Us Advertise With Us Howard Farran DDS, MBA Policies and Agreements
Site Help
The Dentaltown Team, Farran Media Support
Phone: +1-480-445-9710
Email: support@dentaltown.com
©2026 Dentaltown, a division of Farran Media • All Rights Reserved
9633 S. 48th Street Suite 200 • Phoenix, AZ 85044 • Phone:+1-480-598-0001 • Fax:+1-480-598-3450